Fenofibrate

Fenofibrate

Clinical data
Trade names	Fenoglide, Lipofen
AHFS/Drugs.com	Monograph
MedlinePlus	a601052
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	C10AB05 (WHO)
Legal status
Legal status	Legend
Pharmacokinetic data
Protein binding	99%
Metabolism	glucuronidation
Biological half-life	20 h
Excretion	urine (60%), feces (25%)
Identifiers
IUPAC name propan-2-yl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate
CAS Number	49562-28-9 Y
PubChem (CID)	3339
IUPHAR/BPS	7186
DrugBank	DB01039 Y
ChemSpider	3222 Y
UNII	U202363UOS Y
KEGG	D00565 Y
ChEBI	CHEBI:5001 Y
ChEMBL	CHEMBL672 Y
ECHA InfoCard	100.051.234
Chemical and physical data
Formula	C20H21ClO4
Molar mass	360.831 g/mol
3D model (Jmol)	Interactive image
Melting point	80 to 81 °C (176 to 178 °F)
SMILES O=C(c1ccc(Cl)cc1)c2ccc(OC(C(=O)OC(C)C)(C)C)cc2
InChI InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3 Y Key:YMTINGFKWWXKFG-UHFFFAOYSA-N Y

Fenofibrate, marketed as Tricor and under several other brand names, is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels. It is used alone or along with statins in the treatment of hypercholesterolemia and hypertriglyceridemia.

Fenofibrate has been used since 1975 and is one of the most commonly prescribed fibrates.

Fenofibrate is mainly used for primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate appears to decrease the risk of cardiovascular disease and possibly diabetic retinopathy in those with diabetes mellitus, and firstly indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy in Australia. It also appears to be helpful in decreasing amputations of the lower legs in this same group of people. Fenofibrate also has an off-label use as an added therapy of high blood uric acid levels in people who have gout.

It is used in addition to diet to reduce elevated low-density lipoprotein cholesterol (LDL), total cholesterol, triglycerides (TG), and apolipoprotein B (apo B), and to increase high-density lipoprotein cholesterol (HDL) in adults with primary hypercholesterolemia or mixed dyslipidemia.